Compare Advanced Micro Devices (AMD) vs Amgen, Inc. (AMGN) Price & Performance

Advanced Micro DevicesTrade

Amgen, Inc.Trade

Price performance (Past 24H)

Key statistics

Advanced Micro Devices vs Amgen, Inc. — how do they compare? Advanced Micro Devices trades at $480.7 (market cap $774.32B), while Amgen, Inc. trades at $412.21 (market cap $224.14B). The key difference: Advanced Micro Devices is far larger — about 3.5× Amgen, Inc.'s market cap, and Amgen, Inc. pays a 2.43% dividend while Advanced Micro Devices pays none. Which is the better fit depends on your goals.

	AMD	AMGN
Market Cap	$774.32B	$224.14B
Sector	Technology	Health
52-Week High	$580.91	$417.20
52-Week Low	$151.14	$271.18
Enterprise Value	$765.48B	$267.45B
Dividend Yield	—	2.43%

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Advanced Micro Devices

AMD trades at $474.32, down 1.87% on the day, with a bearish technical signal but strong fundamental momentum. The stock shows elevated valuation metrics (P/E 119.79, P/S 18.75) despite impressive revenue growth to $34.64B in 2025 and consistent earnings beats. Analyst consensus remains strongly bullish with a $615.11 price target, while recent news highlights AMD's positioning in the competitive AI semiconductor market.

AMD presents a growth story driven by AI and data center demand, with projected revenue reaching $41.3B in 2026. However, high valuations and intense competition from NVIDIA represent significant risks. The stock offers substantial upside to analyst targets but requires careful monitoring of execution and market share dynamics.

Amgen, Inc.

No Aura AI signal available yet.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

AMD

Polen 5Perspectives Large Growth Portfolio outperforms Russell 1000 Growth with 26.63% return in Q2 2026Seeking Alpha · 13 hours agoBullish NVIDIA stock at $218 balances big AI growth potential with risks from customer concentration and market uncertainty.24/7 Wall Street · 18 hours agoNeutral AMD downgraded to Hold due to valuation concerns and uncertain margin growth despite strong revenue.Seeking Alpha · 1 day agoBearish View details →

AMGN

BioCryst hits profitability with strong Q2 revenue, sparking takeover interest in rare disease biotech.24/7 Wall Street · 1 day agoBullish View details →

About Advanced Micro Devices

Advanced Micro Devices, Inc. (AMD) produces semiconductor products and devices. The Company offers products such as microprocessors, embedded microprocessors, chipsets, graphics, video and multimedia products and supplies it to third-party foundries, as well as provides assembling, testing, and packaging services. AMD serves customers worldwide.

About Amgen, Inc.

Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).